Q-omics provides the consensus-scored AP5S1 profile across patient tissues and cancer cell-line models. AP5S1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AP5S1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, AP5S1 protein abundance shows 19,492 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where AP5S1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AP5S1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AP5S1 survival associations across molecular data types. AP5S1 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AP5S1 RNA expression–survival associations across cancer types. High AP5S1 expression shows unfavorable associations in UVM, KICH, LGG, SKCM, LIHC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for AP5S1 RNA expression.
This table summarizes AP5S1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for AP5S1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AP5S1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, LUSC and BRCA. The HNSC box plot shows higher AP5S1 RNA expression in tumor versus normal tissue (log2 FC = +0.774, t-test p < 0.001).
This table shows molecular features associated with AP5S1 in patient tissues and cancer cell lines. In patient samples, AP5S1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, AP5S1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
